Management of Aripiprazole-Induced Drowsiness in Teenagers

The American Academy of Child and Adolescent Psychiatry notes that somnolence is a significant side effect of aripiprazole in adolescents, alongside weight gain, drooling, tremor, fatigue, and vomiting 1, 2, 3
The European Society for Medical Oncology guidelines state that aripiprazole may cause drowsiness as part of its adverse effect profile, though it is less likely to cause extrapyramidal symptoms compared to first-generation antipsychotics 4

Immediate Assessment Steps

The American Academy of Pediatrics recommends evaluating the timing of drowsiness, determining if sedation occurs primarily after dosing or throughout the day 6
The Journal of the American Academy of Child and Adolescent Psychiatry suggests reviewing the current dosage, as higher doses increase sedation risk 1, 2
The European Society for Medical Oncology guidelines advise checking for drug interactions, particularly with cytochrome P450 2D6 and 3A4 inhibitors that can increase aripiprazole levels and intensify side effects 4

The Journal of the American Academy of Child and Adolescent Psychiatry recommends reducing the aripiprazole dose to the lowest effective level, considering a reduction to 5 mg daily if the patient is on 10-15 mg daily 1, 2
The Annals of Oncology suggests reducing the dose to 2.5 mg daily if the patient is on 5 mg daily 4
The Journal of Clinical Sleep Medicine recommends moving the dose to bedtime if drowsiness persists at lower doses but therapeutic benefit is maintained 7

The American Academy of Pediatrics advises monitoring for fall risk, particularly in adolescents participating in sports or physical activities, and those with concurrent medications that cause sedation 6, 8
The European Society for Medical Oncology guidelines warn against combining aripiprazole with other sedating medications, such as benzodiazepines, antihistamines, or other CNS depressants 4, 6, 8

The European Society for Medical Oncology guidelines note that patients who are poor metabolizers of cytochrome P450 2D6 will have higher aripiprazole levels and more frequent side effects, including drowsiness, and recommend considering genetic testing or empirically reducing the dose by 50% in suspected poor metabolizers 4, 5

The Journal of Clinical Sleep Medicine recommends using standardized scales, such as the Epworth Sleepiness Scale adapted for adolescents, to monitor subjective drowsiness 9